This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Turner, R B Articles by Hayden, F G Search for Related Content PubMed PubMed Citation Articles by Turner, R B Articles by Hayden, F G

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 February; 37(2): 297-300

Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection.

Department of Pediatrics, Medical University of South Carolina, Charleston 29425.

ABSTRACT

The efficacy of oral WIN 54954 for the prevention of rhinovirus infection and illness was tested in two randomized, double-blinded, placebo-controlled volunteer challenge studies. Volunteers were inoculated with rhinovirus type 39 (MIC of WIN 54954, 0.17 microgram/ml) or rhinovirus type 23 (MIC, 0.016 microgram/ml). The volunteers received two doses of drug (600 mg per dose) or placebo on the first day; this was followed by three doses on each of the subsequent 5 days. All volunteers were challenged with virus after the third dose of study drug. No significant antiviral or clinical effect was detected in either study. Pharmacokinetic studies revealed that on the last day of drug administration, 38 of 39 (97%) volunteers had trough levels of WIN 54954 in plasma greater than the MIC for the respective virus. Nasal wash specimens collected on the same day revealed a detectable level in only 6 of 24 (25%) volunteers at the peak (range, 6 to 24 ng/ml) and in only 2 of 14 (14%) volunteers at the trough (range, 6 and 7 ng/ml). These results suggest that the lack of efficacy of WIN 54954 against rhinovirus may be related to an inability to deliver sufficient drug to the site of viral infection.

This article has been cited by other articles:

• Hadfield, A. T., Diana, G. D., Rossmann, M. G. (1999). Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. Proc. Natl. Acad. Sci. USA 96: 14730-14735 [Abstract] [Full Text]  
• Gern, J. E., Busse, W. W. (1999). Association of Rhinovirus Infections with Asthma. Clin. Microbiol. Rev. 12: 9-18 [Abstract] [Full Text]  
• FOLKERTS, G., BUSSE, W. W., NIJKAMP, F. P., SORKNESS, R., GERN, J. E. (1998). Virus-induced Airway Hyperresponsiveness and Asthma. Am. J. Respir. Crit. Care Med. 157: 1708-1720 [Full Text]